You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of recombinant VSV vaccines for emerging bunyaviruses

    SBC: Advac Therapeutic LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Emerging viral infections remain a global threat to human health. Bunyaviruses are the largest order of RNA viruses that includes many clinically relevant human pathogens such as Lassa, Rift Valley Fever and various hantaviruses which cause viral hemorrhagic fever (VHF). SFTSV, or Severe fever with thrombocytopenia syndrome virus, is an emerging tick-borne bunyavirus that ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. TeleLine: Plug-n-Play Inline Respiratory Remote Data Acquisition System

    SBC: OMNIBUS MEDICAL DEVICES, LLC            Topic: NINR

    Project Summary One in five Americans live in a rural community served by rural hospitals yet only 1% of ICU resources are available to these hospitals. When the level of care required by a patient exceeds the capabilities of the admitting hospital, the patient is transferred to a better-equipped tertiary hospital. Approximately 800,000 patients require mechanical ventilation every year in the Uni ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease

    SBC: FURANICA, INC.            Topic: NHLBI

    1 Project Summary2 Cardiovascular risks in dyslipidemia patients are commonly controlled by lowering the LDL-C level using statins.3 However, a significant residual cardiovascular risk persists in patients with additional concurrent risk factors such4 as obesity, diabetes, insulin resistance, and elevated triglyceride-rich lipoproteins. Given the multifaceted5 underlying pathology of cardiovascula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Minimally Invasive On Demand Electrical Nerve Block (OD-ENB) Device for Peripheral Pain

    SBC: H-CUBED            Topic: NIDA

    Knee  Osteoarthritis  (KOA)  is  a  degenerative  joint  disease  that  leads  to  significant  pain  and  functional  disability  affecting  over  30%  of  older  adults  making  it  one  of  the  most  common  and  debilitating  conditions  related  to  aging.  This  disease  results  in  a  loss  of  mobility,  reduced  quality  of  life,  and  in ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. The DOVE Device to Prevent Opioid Overdose Deaths: An Armband That Senses Overdose and Automatically Injects Naloxone

    SBC: Altrumed LLC            Topic: NIDA

    ABSTRACT / PROJECT SUMMARY Despite the wide availability of the antidote naloxone, fatal opioid overdoses still occur at a rate of ~50-70,000 / year in the US. The problem is that naloxone requires a bystander to find and diagnose the overdose, find someone who has naloxone, and then properly administer it. Unfortunately, if this does not occur within 5 minutes, the patient will suffer from brain ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Optimizing the synthesis of[18F]FTMP for commercial distribution

    SBC: VELLUM BIOSCIENCES LLC            Topic: NIBIB

    Abstract The development of genetic medicines such as gene and cell therapies like Chimeric Antigen Receptor (CAR) T cells has necessitated new technologies that can monitor the biodistribution of these therapies in human patients. Imaging is particularly well suited to provide such quantitative measurements of a genetic medicine over time. Vellum Biosciences is a platform imaging company geared t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Physics-informed Machine Learning approach for a selective, sensitive, and rapid sensor for detecting unsafe levels of carcinogenic/toxic VOCs

    SBC: Prometheus Technologies, LLC            Topic: NIEHS

    Project Summary Each year, between 340,000 and 900,000 premature deaths can be linked to air pollution caused by releasing Volatile Organic Compounds (VOCs), i.e., an estimated 1.8 billion tons of VOCs are emitted to the global environment each year. Also, some VOCs cause serious adverse health effects even at the trace level concentration, e.g., cancer, damage to the central nervous and immune sy ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk

    SBC: MOLECULAR TARGETING TECHNOLOGIES, INC.            Topic: NHLBI

    We propose to develop a novel antithrombotic agent with improved efficacy and safety over standard of care via the following properties: 1) specific targeting to procoagulant surfaces, 2) high coagulant site binding and blocking capacity, 3) potent and specific effects of reducing clot size by selectively blocking only highly coagulant sites, 4) reducing bleeding risk compared with current antipla ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Biomimetic Stentless Pulmonary Heart Valve for the Treatment of Pediatric Congenital Heart Disease

    SBC: NEOOLIFE, INC.            Topic: NHLBI

    PROJECT SUMMARY Congenital heart disease (CHD) is caused by defects in the heart structure that occur at birth and affect blood flow through the heart and the rest of the body. CHD affects around 10 out of 1,000 live-born children, 25% of which will need an intervention or surgery within their first year of life. Circa 1 million children and 1.4 million adults live with CHD in the US, and over 182 ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government